Lipomatosis-associated inflammation and excess collagen may contribute to lower relative resting energy expenditure in women with adiposis dolorosa

International Journal of Obesity

Volumn 33, Issue 9, 2009, Pages 1031-1038

  Herbst, K L ^a,b,d   Coviello, A D ^c   Chang, A ^a   Boyle, D L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adiposis dolorosa; IL 6; Dercums disease; Lipomatosis; Resting energy expenditure

Indexed keywords

ADIPONECTIN; COLLAGEN; FRACTALKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; ADIPOCYTOKINE; AUTACOID; CYTOKINE;

ADIPOSE TISSUE; ADIPOSIS DOLOROSA; ADULT; AGE DISTRIBUTION; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CALORIMETRY; CELL INFILTRATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; FEMALE; GIANT CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEAN BODY WEIGHT; LEUKOCYTE MIGRATION; LIPOMATOSIS; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REST; TISSUE LEVEL; ADOLESCENT; BASAL METABOLIC RATE; BLOOD; CASE CONTROL STUDY; ENERGY METABOLISM; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADIPOKINES; ADIPOSE TISSUE; ADIPOSIS DOLOROSA; ADOLESCENT; ADULT; BASAL METABOLISM; CALORIMETRY, INDIRECT; CASE-CONTROL STUDIES; COLLAGEN; CYTOKINES; ENERGY METABOLISM; FEMALE; GIANT CELLS; HUMANS; INFLAMMATION MEDIATORS; LIPOMATOSIS; MIDDLE AGED; REST; YOUNG ADULT;

EID: 70349136255     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.119     Document Type: Article

References (55)

1. Dercum FX. A subcutaneous connective-tissue dystrophy of the arms and back, associated with symptoms resembling myxo-edema. In: University Medical Magazine Philadelphia 1888, vol.1, pp 140-150.
2. Herbst KL, Asare-Bediako S. Adiposis dolorosa is more than painful fat. Endocrinologist 2007; 17: 326-344.
3. Palmer ED. Dercum's disease: adiposis dolorosa. Am Fam Physician 1981; 24: 155-157.
4. Harris K, Davies K, Dumont S, Stephenson BM. A pain in the groin. Lancet 1997; 350: 334.
5. Wortham NC, Tomlinson IP. Dercum's disease. Skinmed 2005; 4: 157-162; quiz 163-1154
6. Brorson H, Fagher B. Dercum's disease Fatty tissue rheumatism caused by immune defense reaction? Lakartidningen 1996; 93: 1430, 1433-1436.
7. Blomstrand R, Juhlin L, Nordenstam H, Ohlsson R, Werner B, Engstrom J. Adiposis dolorosa associated with defects of lipid metabolism. Acta Derm Venereol (1971); 51: 243-250.
8. Pimenta WP, Paula FJ, Dick-de-Paula I, Piccinato CE, Monteiro CM, Brandao-Neto J et al. Hormonal and metabolic study of a case of adiposis dolorosa (Dercum's disease). Braz J Med Biol Res 1992; 25 : 889-893.
9. Taniguchi A, Okuda H, Mishima Y, Nagata I, Oseko F, Hara M et al. A case of adiposis dolorosa: lipid metabolism and hormone secretion. Int J Obes 1986; 10: 277-281.
10. Fagher B, Monti M, Nilsson-Ehle P, Akesson B. Fat-cell heat production, adipose tissue fatty acids, lipoprotein lipase activity and plasma lipoproteins in adiposis dolorosa. Clin Sci (Lond) 1991; 81 : 793-798.
11. Weinsier RL, Bracco D, Schutz Y. Predicted effects of small decreases in energy expenditure on weight gain in adult women. Int J Obes Relat Metab Disord 1993; 17: 693-700.
12. Nielsen S, Hensrud DD, Romanski S, Levine JA, Burguera B, Jensen MD. Body composition and resting energy expenditure in humans: role of fat, fat-free mass and extracellular fluid. Int J Obes Relat Metab Disord 2000; 24: 1153-1157.
13. Steiger WA, Litvin H, Lasche EM, Durant TM. Adiposis dolorsa (Dercum's disease). N Engl J Med 1952; 247: 393-396.
14. Price GE. Adiposis dolorosa. Am J Med 1905; 137: 705.
15. Campen RB, Sang CN, Duncan LM. Case records of the Massachusetts General Hospital Case 25-2006 A 41-year-old woman with painful subcutaneous nodules. N Engl J Med 2006; 355: 714-722.
16. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
17. Pond CM. Adipose tissue and the immune system. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 17-30.
18. Kamimura MA, Draibe SA, Dalboni MA, Cendoroglo M, Avesani CM, Manfredi SR et al. Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrol Dial Transplant 2007; 22: 839-844.
19. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-2386.
20. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
21. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997; 387: 611-617.
22. Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, O'Connor KA et al. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 2004; 20: 2294-2302.
23. Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 2007; 104: 10655-10660.
24. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J et al. Effects of IL-13 on phenotype cytokine production, cytotoxic function of human monocytes. Comparison with IL-4 modulation by IFN-gamma or IL-10. J Immunol 1993; 151: 6370-6381.
25. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-1181.
26. Wang J, Roderiquez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998; 72: 7642-7647.
27. Caspar-Bauguil S, Cousin B, Galinier A, Segafredo C, Nibbelink M, Andre M et al. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett 2005; 579: 3487-3492.
28. Alberici LC, Oliveira HC, Patricio PR, Kowaltowski AJ, Vercesi AE. Hyperlipidemic mice present enhanced catabolism and higher mitochondrial ATP-sensitive K+ channel activity. Gastroenterology 2006; 131: 1228-1234.
29. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther 2003; 5: R352-R360.
30. Cooper BG, McLean JA, Taylor R. An evaluation of the Deltatrac indirect calorimeter by gravimetric injection and alcohol burning. Clin Phys Physiol Meas 1991; 12: 333-341.
31. Peronnet F, Massicotte D. Table of nonprotein respiratory quotient: an update. Can J Sport Sci 1991; 16: 23-29.
32. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109: 1-9.
33. Medicine ACoS. American College of Sports Medicine's Metabolic Calculations Handbook, 2006. Lippincott Williams & Wilkins, Philadelphia, PA, USA.
34. Dore C, Hesp R, Wilkins D, Garrow JS. Prediction of energy requirements of obese patients after massive weight loss. Hum Nutr Clin Nutr 1982; 36C: 41-48.
35. Muffin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 1990; 51: 241-247.
36. Foster GD, Wadden TA, Mullen JL, Stunkard AJ, Wang J, Feurer ID et al. Resting energy expenditure, body composition, and excess weight in the obese. Metabolism 1988; 37: 467-472.
37. Cunningham JJ. Body composition as a determinant of energy expenditure: a synthetic review and a proposed general prediction equation. Am J Clin Nutr 1991; 54: 963-969.
38. Weststrate JA, Dekker J, Stoel M, Begheijn L, Deurenberg P, Hautvast JG. Resting energy expenditure in women: impact of obesity and body-fat distribution. Metabolism 1990;39: 11-17.
39. Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 2004; 89: 5577-5582.
40. Franckhauser S, Elias I, Rotter Sopasakis V, Ferre T, Nagaev I, Andersson CX et al. Overexpression of Il6 leads to hyperinsuli-naemia, liver inflammation and reduced body weight in mice. Diabetologia 2008; 24: 24.
41. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177: 1821-1826.
42. Tsou CL, Haskell CA, Charo IF. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalk-ine. J Biol Chem 2001; 276: 44622-44626.
43. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M et al. Identification and molecular characterization of Fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-530.
44. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 2007; 21: 642-651.
45. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004; 24 : 7353-7365.
46. Terabe M, Park J, Berzofsky J. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004; 53: 79-85.
47. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-2261.
48. Urban Jr Jf, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M et al. IL-13, IL-4Ralpha, Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostron-gylus brasiliensis. Immunity 1998; 8: 255-264. (Pubitemid 28123752)
49. Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999; 162: 920-930.
50. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-520.
51. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G et al. Interleukin 13 induces interleukin 4-independent IgG4 IgE synthesis CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90: 3730-3734.
52. Bogdan C, Thuring H, Dlaska M, Rollinghoff M, Weiss G. Mechanism of suppression of macrophage nitric oxide release by IL-13: influence of the macrophage population (published erratum appears in J Immunol 1999 Mar 1;162(5):3106). J Immunol 1997; 159: 4506-4513.
53. Pope Sm, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- eotaxin-dependent mechanism. J Allergy Clin Immunol 2001; 108: 594-601.
54. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP et al. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995; 154: 799-803.
55. Manna Sk, Aggarwal BB. IL-13 suppresses TNF-induced activation of nuclear factor-kappa B activation protein-1 apoptosis. J Immunol 1998; 161: 2863-2872.